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Abstract
Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae are major bacterial agents of meningitis. They
each bind the 37/67-kDa laminin receptor (LamR) via the surface protein adhesins: meningococcal PilQ and PorA, H.
influenzae OmpP2 and pneumococcal CbpA. We have previously reported that a surface-exposed loop of the R2 domain of
CbpA mediates LamR-binding. Here we have identified the LamR-binding regions of PorA and OmpP2. Using truncated
recombinant proteins we show that binding is dependent on amino acids 171–240 and 91–99 of PorA and OmpP2,
respectively, which are predicted to localize to the fourth and second surface-exposed loops, respectively, of these proteins.
Synthetic peptides corresponding to the loops bound LamR and could block LamR-binding to bacterial ligands in a dose
dependant manner. Meningococci expressing PorA lacking the apex of loop 4 and H. influenzae expressing OmpP2 lacking
the apex of loop 2 showed significantly reduced LamR binding. Since both loops are hyper-variable, our data may suggest a
molecular basis for the range of LamR-binding capabilities previously reported among different meningococcal and H.
influenzae strains.
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Introduction
Invasive disease caused by Neisseria meningitidis (meningococcus),
Haemophilus influenzae and Streptococcus pneumoniae (pneumococcus)
remains an important cause of morbidity and mortality worldwide,
despite the use of antibiotics and the introduction of effective
conjugate polysaccharide vaccines that target some disease-
associated serogroups [1]. However, there is no currently licensed
vaccine effective against serogroup B meningococcus, the domi-
nant serogroup in much of the developed world [2]. Similarly,
there are no vaccines against non-type B H. influenzae and the
vaccines available against pneumococcus only provide protection
against a limited subset of the plethora of recognized serogroups
[1].
The human 37/67-kDa laminin receptor (LamR) is a highly
conserved, multi-functional protein [3]. The relationship between
the 37-kDa and 67-kDa forms is not completely understood, but
the former is thought to mature into one or more homo or
heterodimeric 67-kDa forms [4,5,6]. LamR was initially identified
as a cell surface receptor for the extracellular matrix molecule
laminin [7,8,9]. LamR is important for cell adhesion to the
basement membrane and is also implicated in tumour cell
metastasis [10]. LamR has additional roles in intracellular
signaling [11], ribosomal activity [12] and cell viability [13].
LamR can also migrate to the nucleus where it can bind the
histones H2A, H2B and H4, although the significance of this is not
known [14].
Various neurotropic bacteria and viruses use LamR as a
receptor to bind host microvascular endothelial cells. Viruses
including Sindbis [15], dengue [16], adeno-associated [17], tick-
borne encephalitis [18] and Venezuelan equine encephalitis
viruses [19] bind LamR. The cytotoxic necrotizing factor toxin
(CNF1) of Escherichia coli [20] and the cellular prion protein PrP
[21] also interact with LamR.
Recently we showed that binding to LamR is a common
mechanism employed by S. pneumoniae, N. meningitidis and H.
influenzae to adhere to human brain microvascular endothelial cells
[22]. The bacterial ligands responsible for LamR binding were
identified as pneumococcal CbpA, meningococcal PilQ and PorA
and H. influenzae OmpP2 [22]. All are abundant, multi-functional
proteins with surface-exposed loop structures. In particular,
meningococcal PorA and H. influenzae OmpP2 share many
characteristics, despite showing limited sequence similarity. Both
are homo-trimeric outer membrane porins with amphipathic b-
barrel structures forming sixteen membrane-spanning b-strands
separating more variable sequences forming eight surface exposed
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loops [23,24]. In the case of OmpP2, most sequence variability
occurs in the second, fourth, fifth and eighth loops (known as
variable regions 1, 2, 3 and 4, respectively) [25,26], whereas in
PorA most variation occurs in the first, fourth and fifth loops
(variable regions 1, 2 and 3, respectively) [27,28]. Indeed sequence
variability of PorA is the basis of the meningococcal subtyping
strategy [29,30,31].
As immunodominant antigens and targets for serum bacteri-
cidal antibodies, PorA and OmpP2 have been studied as potential
vaccine targets [32,33]. However, bactericidal antibodies elicited
by such vaccines predominately target the variable extra-cellular
loops [23,27,34]. Therefore, generating an immune response
against one antigen does not generally confer protection against
strains with heterologous antigens.
Previously, we showed that the highly conserved surface-
exposed loop (residues 391EPRNEEK397) linking the second and
third anti-parallel a-helices of the R2 domain of pneumococcal
CbpA mediated LamR-binding [22]. Here, using recombinant
derivatives of PorA and OmpP2, synthetic peptides corresponding
to their extracellular loops, and bacterial strains expressing LamR
ligands in which specific extracellular loops were deleted, we
identify the fourth and second extra-cellular loops of PorA and
OmpP2, respectively, as the LamR-binding domains of these
proteins.
Results
Amino acids 171–240 of recombinant PorA exhibit LamR-
binding activity
To identify the regions of N. meningitidis MC58 PorA that elicit
LamR binding activity, recombinant PorA (minus the 19 amino
acid cleavable N-terminal signal peptide; PorA20–392) and three
sub-fragments of PorA (PorA20–170, PorA20–258 and PorA20–332;
Fig. 1A) were expressed and purified. LamR-binding activity of
PorA20–170 was significantly reduced compared to PorA20–392 in
ELISA assays (Fig. 1B). This suggested that the LamR-binding
region was localized between amino acids 171–258. The sub-
fragments PorA95–170 and PorA150–258 (Fig. 1A) were subsequently
tested in ELISA assays; binding of PorA150–258 was not signifi-
cantly different from PorA20–392 (Fig. 1C). As expected, PorA95–170
showed significantly reduced LamR-binding when compared to
PorA20–392.
Next, derivatives of PorA20–392 were expressed in which the
residues spanning loop 4 were removed (PorAD169–240). This
derivative showed significantly less LamR-binding activity than
PorA20–392 (Fig. 1D). In contrast, control PorA derivatives lacking
parts of loops 1 (PorAD58–94) or 3 (PorAD125–149) exhibited similar
LamR binding to PorA20–392, providing additional confirmation
that these regions are not required for optimal LamR binding
(Fig. 1D). Taken together these results indicated that the LamR-
binding domain of MC58 PorA lies within amino acids 171–240
and was likely localized to the fourth extra-cellular loop which
comprises amino acids 185–218.
Amino acids 91–99 of recombinant OmpP2 exhibit LamR-
binding activity
In a similar approach to that used to identify the LamR-binding
region of N. meningitidis MC58 PorA, recombinant H. influenzae Rd
KW20 OmpP2 (minus the first 23 N-terminal amino acids;
OmpP224–359) and two sub-fragments (OmpP224–225 and
OmpP2224–359; Fig. 2A) were expressed and purified. Of the two
sub-fragments, OmpP2224–359 showed significantly less LamR-
binding compared to OmpP224–359 (Fig. 2B). This suggested that
the LamR-binding region was localized between amino acids 24–
224.
We hypothesized that the LamR-binding activity was localized
to one of the extra-cellular loops of OmpP2 between amino acids
24–224; four derivatives of OmpP224–359 were expressed and
purified in which the residues spanning the apical regions of loops
1, 2, 3 or 4 were removed. The derivative lacking loop 2
(OmpP2D91–99) showed significantly less LamR binding activity
compared to OmpP224–359 (Fig. 2C), whilst the other derivatives
lacking loops 1, 3 or 4 showed no significant reductions in binding.
These results indicated that the LamR-binding domain of OmpP2
lies within amino acids 91–99, corresponding to the apical region
of the second extra-cellular loop, which comprises amino acids 88–
102.
Synthetic peptides corresponding to PorA loop 4 and
OmpP2 loop 2 bind LamR and block ligand-LamR
binding
Further characterization of the PorA and OmpP2 LamR-
binding domains was undertaken using synthetic peptides. Several
peptides were synthesized (Table 1): one corresponding to the 9-
amino acid apical region of OmpP2 loop 2 (residues 91–99);
another corresponding to the 34-amino acids of PorA loop 4
(residues 185–218), which we hypothesized was responsible for
PorA-LamR binding; and a third corresponding to PorA loop 1
(residues 31–70) for use as a non-LamR binding control peptide.
In addition, scrambled peptides based on OmpP2 loop 2 and PorA
loop 4 were also synthesized. Each peptide included additional
terminal cysteine residues; under oxidizing conditions cysteine
sulfhydryl groups spontaneously form disulfide bonds, thus
allowing the peptides to circularize and more closely mimic the
native loop structures. PorA loop 1 and the two scrambled
peptides (PorA loop 4scr and OmpP2 loop 2scr) bound less than
either OmpP2 loop 2 or PorA loop 4 to LamR (Fig. 3A).
Furthermore, PorA loop 4, but not PorA loop 1 could block the
binding of soluble LamR to the solid-phase ligand PorA20–392 in a
dose-dependent manner (Fig. 3B).
Loop 4 residues 192–208 are required for optimal LamR-
binding
Experiments were undertaken to further define the region
within the 34-amino acid PorA loop 4 required for optimal LamR
binding. Five overlapping peptides (L4_1 to L4_5) were synthe-
sized spanning loop 4 (Table 1 & Fig. 4A). The peptides were
immobilized in microtitre wells and DIG-labeled LamR added.
After washing, bound LamR was detected and quantified (Fig. 4B).
As expected, the control non-LamR binding control peptide (loop
1) showed significantly less binding to LamR compared to whole
loop 4. Two of the shorter loop 4 peptides (L4_4 and L4_5)
showed significantly reduced LamR-binding compared to whole
loop 4 (p,0.05), whilst L4_1 showed reduced binding, albeit it not
reaching statistical significance (p=0.069). The highest LamR-
binding was exhibited by L4_2 and also L4_3, which correspond
to the most apical part of loop 4 and together span PorA192–208
suggesting that the key residue(s) mediating LamR-binding are
localized in this region.
Deletion of N. meningitidis PorA loop 4 or H. influenzae
OmpP2 loop 2 reduces LamR-binding
To determine whether the LamR-binding activity of PorA loop
4 observed using synthetic peptides and recombinant sub-
fragments reflect the ability of the protein in situ in the bacterial
cell to mediate binding to LamR, a derivative of the N. meningitidis
LamR-Binding Domains of PorA and OmpP2
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strain MC58 was constructed in which the central 14 amino acids
of PorA loop 4 were deleted (MC58PorAD197–210). We have
previously shown that meningococci have two LamR-binding
ligands: PorA and PilQ, and that in the presence of PilQ, deletion
of PorA has relatively little effect on observable LamR-binding
[22]. Therefore, we introduced a pilQ mutation into the
MC58PorAD197–210 genetic background to create
MC58PorAD197–210DpilQ to enable us to specifically address the
effect of loop 4 truncation on PorA-mediated LamR-binding.
Truncating loop 4 did not interfere with expression of PorA or the
ability of the protein to correctly localize to the meningococcal
outer membrane. Immunoblots of cell fractions confirmed the
presence of PorAD197–210 at similar levels to wild-type PorA in
meningococcal outer membrane-enriched sub-cellular fractions
(Fig. 5A). In addition, a mouse monoclonal antibody directed
against loop 1 bound to the surface of strains expressing wild-type
PorA or PorAD197–210 at similar levels as observed by confocal
microscopy, but not in strains where porA had been inactivated
(Fig. 6). LamR-binding exhibited by MC58PorAD197–210DpilQ was
significantly reduced and similar to the control strain lacking PorA
and PilQ (Fig. 7A), thus confirming that the apical region of loop 4
determines PorA-mediated LamR binding by N. meningitidis
MC58.
Similarly, we constructed a H. influenzae Rd KW20 derivative in
which the amino acids 91–99 were deleted (RdOmpP2D91–99).
Again, prior to determining the LamR-binding potential of this
strain, we first confirmed that truncating loop 2 did not interfere
with expression of OmpP2 or the ability of the protein to correctly
localize to the H. influenzae outer membrane (Fig. 5B). LamR-
binding by RdOmpP2D91–99 was significantly reduced compared
to the wild-type (p,0.01), albeit the reduction in LamR-binding
was not as great as that observed for the control strain lacking
Figure 1. Amino acids 171–240 of recombinant PorA exhibit LamR-binding activity. (A) Schematic showing the recombinant derivatives of
N. meningitidis MC58 PorA utilized in this study and a summary of their respective LamR-binding activities. L1–L8 denotes the eight extra-cellular
loops based on the model of van der Ley et al. [23]. (B) Binding of LamR to the solid phase antigens PorA20–392, PorA20–170, PorA20–258 and PorA20–332.
(C) Binding of LamR to PorA20–392, PorA95–170 and PorA150–258. (D) Binding of LamR to PorA20–392, PorAD58–94, PorAD125–149 and PorAD169–240. Data
shown in each panel are means from three independent experiments; in each experiment each sample was tested in triplicate. ** p,0.01 compared
to binding with matching PorA20–392 samples. Error bars indicate SEM.
doi:10.1371/journal.pone.0046233.g001
LamR-Binding Domains of PorA and OmpP2
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OmpP2 (Fig. 7B), perhaps indicating that additional residues of
OmpP2 may play a role in optimizing LamR-binding. Control
strains with an antibiotic cassette inserted at the porA or ompP2
locus, but no modification to either the porA or ompP2 coding
sequence, showed no significant reduction in LamR-binding, thus
confirming the direct effect of removing or truncating porA or
ompP2 on binding (data not shown).
In summary, we have identified the apical regions of the fourth
and second extra-cellular loops of meningococcal MC58 PorA and
H. influenzae Rd KW20 OmpP2, respectively, as the LamR-
binding regions of these bacterial ligands.
Discussion
Several neurotropic pathogens bind to the 37/67-kDa laminin
receptor on host microvascular endothelial cells. In particular, this
adherence strategy is used by the bacterial pathogens S. pneumoniae,
N. meningitidis and H. influenzae [22]. These species target a
common carboxy-terminal recognition site on LamR (amino acids
263–282), since antibodies recognizing this sequence or a peptide
corresponding to LamR residues 263–282 could inhibit bacterial
binding to microvascular endothelial cells [22]. The bacterial
ligands required for LamR-binding were subsequently identified as
pneumococcal CbpA, meningococcal PilQ and PorA and H.
influenzae OmpP2 [22]. Understanding the structural basis for the
ability of these ligands to bind LamR could facilitate the design of
therapeutic interventions which could prevent or disrupt the
interaction and thus engender protection against bacterial
meningitis.
To this end, we previously investigated the LamR-binding
region of CbpA: a secreted protein that acts as a bridging adhesin
to human cells [35]. The CbpA LamR-binding region mapped to
a highly conserved surface-exposed loop (residues 391EPR-
NEEK397) linking the second and third anti-parallel a-helices of
the R2 domain. Pneumococcal strains which failed to bind LamR
were shown to have this region missing from CbpA [22]. Two
residues within this region were found to be particularly important
for LamR binding; pneumococci expressing a CbpAP392G-R393G
derivative showed significantly reduced binding to recombinant
LamR and endothelial cells. CbpAP392G-R393G-coated micro-
spheres showed significantly reduced binding to mouse cerebral
endothelium compared to those bearing wild-type CbpA [22].
Figure 2. Amino acids 91–99 of recombinant OmpP2 exhibit LamR-binding activity. (A) Schematic showing the recombinant derivatives of
H. influenzae Rd KW20 OmpP2 utilized in this study and a summary of their respective LamR-binding activities. L1–L8 denotes the eight extra-cellular
loops based on the model of Srikumar et al. [24]. (B) Binding of LamR to the solid phase antigens OmpP224–359, OmpP224–225 OmpP2224–359. (C)
Binding of LamR to OmpP224–359, OmpP2D45–61, OmpP2D91–99, OmpP2D125–151 and OmpP2D177–195. Data shown in each panel are means from three
independent experiments; in each experiment each sample was tested in triplicate. ** p,0.01 compared to binding with matching OmpP224–359
samples. Error bars indicate SEM.
doi:10.1371/journal.pone.0046233.g002
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Importantly, in a mouse model of pneumococcal meningitis,
strains expressing CbpAP392G-R393G rarely caused meningitis
compared to strains expressing wild-type CbpA, thus underlining
the in vivo significance of these key residues in the disease process in
the mouse model [22].
In this study, we undertook to define the regions of meningo-
coccal PorA and H. influenzae OmpP2 required for LamR-binding.
Both are abundant outer membrane trimeric porins that contain
multiple surface-exposed loop structures, but lack sequences
resembling the CbpA LamR-binding domain. Using sub-frag-
ments of recombinant MC58 PorA and Rd KW20 OmpP2, our
results suggest that their LamR-binding domains are localized to
amino acids 171–240 and amino acids 91–99 respectively, since
derivatives containing these regions bound LamR; in contrast
derivatives lacking these regions showed significantly reduced
LamR-binding. For both PorA and OmpP2, predicted surface-
exposed loops mapped to these LamR-binding regions. The
importance of these loops was confirmed using synthetic peptides
based on their sequences. Peptides corresponding to either PorA
loop 4 or OmpP2 loop 2 bound LamR, whilst scrambled peptides
based on these loops or a peptide based on PorA loop 1 bound less
well. Additionally, PorA loop 4 could significantly inhibit binding
of LamR to full-length PorA in contrast to PorA loop 1.
To further refine the region within the 34-amino acid loop 4
required for optimal LamR-interaction, the binding abilities of
shorter overlapping peptides spanning the loop were determined.
This approach was not undertaken for OmpP2 loop 2, since our
data already indicated that optimal binding was dependant on a
short 9-amino acid region (residues 91–99) corresponding to the
apex of the loop. Likewise for PorA loop 4, the highest LamR-
binding was exhibited by short peptides mapping to the loop apex,
suggesting that the key residue(s) mediating binding are localized
to this region.
LamR-binding exhibited by synthetic peptides or ligand sub-
fragments purified under non-native conditions might not
accurately reflect the ability of native ligands embedded in the
Gram negative outer membrane to interact with LamR. We
therefore confirmed our findings using H. influenzae and menin-
gococcal LamR-ligands expressed in their in vivo context. H.
influenzae Rd KW20 expressing OmpP2 containing a 9-amino acid
deletion from the apex of loop 2 showed significantly reduced
LamR-binding compared to wild-type. However, LamR-binding
was not reduced to the level determined for the H. influenzae
DompP2 control strain, indicating that residues outside of the
deleted region may also have a minor effect to modulate binding.
Recent investigations into the role of OmpP2 and its loops in
pathogenesis have focused on the ability of the protein and some of
its loops (principally loop 7) to activate host signaling cascades
(including the mitogen-activated protein kinase cascade) and
initiate the innate immune response (inducing the release of
TNF-alpha and IL-6) in a variety of human cell types
[36,37,38,39]. Here we show that, in addition to the demonstrated
role of OmpP2 loop 7 in pathogenesis, loop 2 is also biologically
relevant as it largely determines the LamR binding activity of
OmpP2.
Our analysis of PorA-mediated LamR-binding in the menin-
gococcus was complicated by the presence of PilQ, the second
LamR ligand expressed by this organism. Consequently, our
LamR-binding experiments were undertaken in pilQ knockout
Figure 3. PorA loop 4 and OmpP2 loop 2 peptides bind LamR.
(A) Binding of LamR to OmpP2 loop 2 (labeled L2), OmpP2 loop 2scr
(L2scr), PorA loop 4 (L4), PorA loop 4scr (L4scr) or PorA loop 1 (L1)
coated ELISA plates. Results shown are means of triplicate wells from a
representative example from two independent experiments. (B) Binding
of DIG-labeled LamR to PorA20–392 in the presence of 0.5, 10, 50 or
100 mg of peptide corresponding to PorA loop 4 (L4) or loop 1 (L1). The
binding of LamR to PorA20–392 in the absence of peptide served as a
negative control for inhibition. * p,0.05 compared to binding in the
absence of peptide. ** p,0.01 compared to binding in the absence of
peptide. Data shown are means from three independent experiments;
in each experiment each sample was tested in triplicate. Error bars
indicate SEM.
doi:10.1371/journal.pone.0046233.g003
Table 1. Synthetic peptides used in this study.
Peptide name Peptide sequence
OmpP2 loop 2 CASENGSDNFCa
OmpP2 loop 2scr CSNGFEDNSACa
PorA loop 4 CPIQNSKSAYTPAYYTKNTNNNLTLVPAVVGKPGSCa
PorA loop 4scr CNSNGATGKNPPVVTLKKSVYQSNYTAPYANTILPCa
PorA loop 1 CVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKICa
L4_1 PIQNSKSAYT
L4_2 AYTPAYYTKN
L4_3 TKNTNNNLTL
L4_4 LTLVPAVVG
L4_5 PAVVGKPGS
aPeptide sequence includes terminal cysteine residues to facilitate disulfide
bond formation.
doi:10.1371/journal.pone.0046233.t001
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derivatives of MC58 to exclude the effects of this protein.
Importantly, N. meningitidis expressing PorA lacking 14-amino
acids from the apex of loop 4 exhibited a significant reduction in
LamR-binding compared to strains expressing wild-type PorA. In
fact, removing these amino acids from PorA in a pilQ knockout
background, reduced LamR-binding to levels indistinguishable
from that of a pilQ porA double knockout mutant. Importantly, this
was not due to the inability of the modified PorA to insert into the
meningococcal outer membrane. Based on our data, we conclude
that the fourteen amino acids of loop 4 represent the sole LamR-
binding domain of PorA in this strain. Further deletions or site-
directed mutagenesis of residues in this region of PorA may lead to
further refinement of this binding domain.
Loop 2 corresponds to variable region 1 of OmpP2 [24]. Thus,
antigenic variation at this loop is likely to explain the varying
LamR-binding capabilities of H. influenzae isolates reported
previously [22]. Similarly, the fourteen amino acid LamR-binding
region of PorA corresponds to the VR2 of this antigen. Our
identification of VR2 as the LamR-binding of PorA in this study is
consistent with previous observations from an experiment in which
porA of a meningococcal isolate with a low LamR-binding activity
(Z4682) was replaced with porA from MC58 [22]. Strain Z4682
bound LamR at 50% of the level of MC58; following the porA
replacement, LamR-binding was increased to 94% of MC58 [22].
The PorA variants (VR1, VR2) of MC58 and Z4682, respectively,
are: 7, 16-2 and 7.1, 1 (http://pubmlst.org/neisseria/PorA/).
Differences in VR1 sequence between variants 7 and 7.1 are
minor, involving the presence/absence of a duplication of two
residues. In contrast, the differences in amino acid sequence
between VR2 variants 16-2 and 1 are considerable (16-2:
YYTKNTNNNLTLVP; 1: YVAVENGVAKKVA). Since VR1
corresponds to loop 1, and VR2 to loop 4, this provided
circumstantial evidence linking loop 4, but not loop 1 to
differences in LamR-binding ability. Here, using a comprehensive
approach involving PorA sub-fragments, synthetic peptides and
meningococcal strains expressing PorA in which specific extracel-
lular loops were deleted, we confirm that the fourth extra-cellular
loop is the LamR-binding region of this protein.
Since over 630 PorA VR2 variants (classified into 20 families)
have been identified across meningococcal isolates to date, we
suggest that the LamR-binding ability conferred by PorA is
variable between strains. In contrast, since PilQ is highly
conserved ($98% identity at amino acid level between genome
sequenced meningococcal strains), we hypothesize that PilQ
confers a relatively constant LamR-binding capability to strains
of different lineages. We are currently determining the LamR-
binding domain(s) of PilQ to allow us to investigate this further.
Why the meningococcus has evolved to express two LamR-
binding ligands, whilst H. influenzae and pneumococcus both
express only one is unclear. However, meningococci have
previously been reported to express multiple adhesins with
overlapping ligand-binding capabilities [40]. Functional redun-
dancy is required to maintain colonization because of the
propensity of the organism to phase and/or antigenically vary its
surface structures. PorA is one such variable surface structure; in
addition to being antigenically variable, PorA expression levels
vary between isolates and within a population of the same isolate.
This is a result of slipped-strand mispairing at a homopolymeric
tract in the porA promoter [41]. In addition, PorA expression may
be absent altogether due to: slipped-strand mispairing at a
homopolymeric tract within the porA gene [41]; deletion of porA
[42]; or via the insertion of an IS element [43]. Whether PilQ
Figure 5. Immunoblots confirm the presence of truncated
porins in outer membrane-enriched sub-cellular fractions. Inner
and outer membrane fractions (labeled IM and OM, respectively) of
MC58 wild-type, MC58PorAD197–210DpilQ (labeled D197–210) and
MC58DporADpilQ double mutant (labeled DPP) (A) or H. influenzae Rd
KW20 wild-type, OmpP2D91–99 and DompP2 (B) were probed with anti-
PorA monoclonal antibody or rabbit polyclonal anti-OmpP2, respec-
tively.
doi:10.1371/journal.pone.0046233.g005
Figure 4. LamR binding activity of PorA loop 4 peptides. (A)
Schematic showing the sequence of the overlapping loop 4 peptides
(L4_1 to L4_5) and alignment to the MC58 PorA loop 4 sequence (L4).
(B) ELISA data showing the binding of LamR to immobilized loop 1 and
loop 4 synthetic peptides. Data shown are means from at least three
independent experiments; in each experiment each sample was tested
in triplicate. * p,0.05 compared to binding of LamR to whole loop 4
(L4). Error bars indicate SEM.
doi:10.1371/journal.pone.0046233.g004
LamR-Binding Domains of PorA and OmpP2
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expression is varied in similar ways and if so, what the genetic
mechanisms governing this variation are, are not currently known.
However, we suggest that the meningococcus utilizes two LamR-
ligands in order to maintain a degree of LamR-binding capability,
irrespective of changes in PorA (or possibly PilQ) expression,
during the infection process. Since meningococci are normally
commensal organisms inhabiting the nasopharynx, and infection
of the meninges represents a relatively rare event that is unlikely to
contribute to the dissemination of this accidental pathogen,
selective pressure leading to such functional redundancy is likely
to be applied at mucosal surfaces and not at the meninges.
In summary, we have identified the LamR-binding regions
within meningococcal PorA and H. influenzae OmpP2. These
regions correspond to the apical regions of the fourth and second
extra-cellular loops, respectively. Both loops are hyper-variable,
suggestive of the molecular basis for the diverse range of LamR-
binding capabilities previously reported for meningococcal and H.
influenzae strains of different lineages. Increased knowledge of the
structural motifs of bacterial ligands that interact with LamR may
facilitate the design of therapeutic interventions which could
disrupt or modulate the interaction of neuroinvasive bacteria with
LamR and engender protection against bacterial meningitis.
However, given that both OmpP2 loop 2 and PorA loop 4 are
hyper-variable, this may hinder the design of strategies to block
LamR-binding, which are effective against a wide range of
pathogenic strains.
Materials and Methods
Bacterial strains and growth conditions
Escherichia coli JM109 was used as the host strain for mutagenic
constructs and for expression of 66 histidine-tagged recombinant
protein fragments (Table S1). This strain was grown at 37uC in
Figure 7. Deletion of PorA loop 4 or OmpP2 loop 2 significantly
reduces bacterial LamR-binding. Binding of (A) N. meningitidis
MC58, MC58PorAD197–210DpilQ and MC58DporADpilQ or (B) H. influenzae
Rd KW20, RdOmpP2D91–99 or RdDompP2 to LamR. Specific binding of
digoxigenin-labeled bacteria to LamR-coated ELISA plates was deter-
mined by subtracting the absorbance in BSA-coated wells from that in
LamR-coated wells. Data shown in each panel are means from three
independent experiments; in each experiment each sample was tested
in triplicate. ** p,0.01 compared to wild-type. Error bars indicate SEM.
doi:10.1371/journal.pone.0046233.g007
Figure 6. Deletion of loop 4 does not affect insertion of PorA
into the meningococcal outer membrane. Immuno-fluorescent
images of (A) MC58 wild-type, (B) MC58PorAD197–210DpilQ or (C)
MC58DporADpilQ. Intact cells of N. meningitidis were probed with
FM1-43 membrane stain (upper panels) and anti-meningococcal
serosubtype P1.7 monoclonal antibody (centre panels). Merged images
(lower panels) depict co-localization of FM1-43 (green) and anti-
meningococcal serosubtype P1.7 monoclonal antibody (red), in yellow.
Phase images (bottom panels) verify the presence of immuno-targets.
Insets shown are at 2.56 field magnification. Scale bar: 5 mm.
doi:10.1371/journal.pone.0046233.g006
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Lysogeny Broth (LB) or on LB agar supplemented, where
appropriate, with ampicillin, kanamycin or streptomycin and
spectinomycin (all at 100 mg ml21). N. meningitidis strains were
grown at 37uC, in an atmosphere of air plus 5% CO2, on
Columbia agar with chocolated horse blood (Oxoid) or in Brain
Heart Infusion (BHI) broth (Oxoid) supplemented, where appro-
priate, with streptomycin and spectinomycin (100 mg ml21) and/
or kanamycin (50 mg ml21). H. influenzae strains were grown at
37uC, in an atmosphere of air plus 5% CO2, on Columbia agar
with chocolated horse blood (Oxoid) or in BHI broth supple-
mented with haemin (10 mg ml21) and NAD (10 mg ml21), and
where appropriate, with kanamycin (50 mg ml21).
DNA manipulation
Chromosomal DNA was purified using the DNeasy Tissue kit
(Qiagen). Plasmid DNA was prepared by using the QIAprep Spin
kit (Qiagen). Restriction enzymes were purchased from Roche and
used according to the manufacturer’s instructions. DNA sequenc-
ing was carried out on an ABI 377 automated DNA sequencer at
the School of Biomedical Sciences (University of Nottingham).
Construction of plasmids encoding PorA sub-fragments
The plasmids encoding PorA20–392, PorA20–170, PorA20–258 and
PorA20–332 were obtaining by amplifying porA fragments from N.
meningitidis MC58 using a common forward oligonucleotide primer
(porA-F1; Table S2) incorporating a BamHI restriction site, and
reverse primers porA-R, porA-R1, porA-R2 and porA-R3,
respectively, incorporating SalI restriction sites. The resulting
amplicons were BamHI/SalI-digested and ligated into BamHI/
SalI-digested pQE30 to yield pPorAQE30, pPorA20-170,
pPorA20-258 and pPorA20-332, respectively (Table S1). The
construct for expression of PorA95–170 was obtained by performing
inverse PCR using pPorA20-170 as template DNA. The primers
used for this (porA-F2 and porA-R4; Table S2) incorporated BglII
restriction sites into the amplicon, allowing re-ligation of the
product following appropriate enzymatic treatment to yield
pPorA95-170. An identical strategy was used to generate
pPorA150-258, but utilizing pPorA20-258 as template DNA and
primers porA-F3 and porA-R4 (Table S2). Inverse PCR, using
pPorAQE30 as template, was utilized to obtain PorAD58–94,
PorAD125–149 and PorAD169–240. The primers pairs used for this:
porA-F4/-R5 (PorAD58–94), porA-F3/-R6 (PorAD125–149) and
porA-F5/-R7 (PorAD169–240) incorporated BglII restriction sites
into the amplicon, allowing re-ligation of the product following
BglII treatment to yield pPorAD58–94, pPorAD125–149 and
pPorAD169–240, respectively (Table S1).
Construction of plasmids encoding OmpP2 sub-
fragments
The plasmid encoding OmpP224–359 was obtaining by ampli-
fying ompP2 from H. influenzae Rd KW20 using primers P2F1
(incorporating a BamHI restriction site; Table S2) and P2R1
(incorporating a SalI restriction site). The resulting amplicon was
BamHI/SalI-digested and ligated into BamHI/SalI-digested
pQE30 to yield pNJO74 (Table S1). The plasmid encoding
OmpP2224–359 was constructed by inverse PCR using pNJO74 as
template and P2D1-4I_F and P2D1-4I_R primers (Table S2). The
amplified product was BamHI-digested and then re-ligated to yield
pMSA1 (Table S1). The plasmid encoding OmpP224–225 was also
constructed by IPCR using pNJO74 as template, but utilizing
P2D5-8I_F and P2D5-8I_R primers (Table S2). The amplified
product was SalI-digested and then re-ligated to yield pMSA2
(Table S1). Inverse PCR using pNJO74 as template was also
utilized to derive the plasmids encoding OmpP2 lacking loop 1, 2,
3 or 4. Primer pairs utilized were: P2DL1I_F and P2DL1I_R (loop
1 deletion), P2DL2I_F and P2DL2I_R (loop 2 deletion),
P2DL3I_F and P2DL3I_R (loop 3 deletion) and P2DL4I_F and
P2DL4I_R (loop 4 deletion; Table S2). These primers incorpo-
rated BglII restriction sites into the amplicons, allowing re-ligation
of the products following appropriate enzymatic treatment to yield
pMSA3, pMSA4, pMSA5 and pMSA6, respectively (Table S1).
Protein expression and purification
Recombinant histidine-tagged LamR was purified as described
previously [22]. For the expression of PorA and OmpP2
derivatives, plasmids were transformed into E. coli JM109, cultures
grown to exponential phase (OD600.0.5) and induced with
isopropyl b-D-1-thiogalactopyranoside (IPTG; 1 mM) for 3 h.
Recombinant proteins were then affinity-purified using HisPurTM
Cobalt Resin (Pierce) under denaturing conditions using a
previously described method [44]. Final column elutes were buffer
exchanged into 16 PBS using PD-10 desalting columns (GE
Healthcare) according to the manufacturer’s instructions.
SDS-PAGE and immunoblotting
Proteins were electrophoretically separated using polyacryl-
amide gels (Mini-Protean III; Bio-Rad). Proteins were stained
using SimplyBlue SafestainTM (Invitrogen) or transferred to
nitrocellulose membranes. Membranes were probed with either
mouse anti-pentahistidine antibody (Qiagen; 1:5000 diluted) or
mouse monoclonal anti-PorA (NIBSC code: 01/514; 1:5000
diluted) or rabbit polyclonal anti-OmpP2 (1:5000 diluted) in
blocking buffer (5% [wt/vol] non fat dry milk, 0.1% [vol/vol]
Tween 20 in 16 phosphate-buffered saline [PBS]) and incubated
for 2 h. After being washed in PBS with 0.1% Tween 20,
membranes were incubated for 2 h with 1:30,000-diluted goat
anti-mouse (or anti-rabbit) IgG-alkaline phosphatase conjugate
(Sigma) and washed with PBS with 0.1% Tween 20. Immunoblots
were developed using BCIP/NBT-Blue liquid substrate (Sigma).
DIG-labeling of proteins and bacteria
DIG-labeling was carried using the Roche DIG-NHS Protein
labeling kit, used as per manufacturer’s instructions. Briefly, for
protein the pH was adjusted to pH 9.0 by addition of 2 M sodium
carbonate, and DIG-NHS reagent added in a 1:10 molar ratio.
Reactions were incubated at room temperature for 1 h, and then
unbound DIG-NHS was removed using PD-10 desalting columns
(GE Healthcare). For bacteria, cells were harvested from an
overnight plate, washed 3 times in PBS with 0.05% Tween 20
(PBST) and resuspended in sodium carbonate buffer (150 mM;
142 mM NaHCO3, 8 mM Na2SO3, pH 9.0). Bacteria (optical
density at 600 nm=1.0) were then labeled with 10 mg ml21 DIG-
NHS at room temperature for 30 min. Bacteria were then washed
3 times with PBST and resuspended in PBS containing 1% bovine
serum albumin (BSA; Sigma).
Enzyme-linked immunosorbent assays
100 ml aliquots of 5 mg ml21 protein in sodium carbonate buffer
were added to a CovaLink NH microplate (Nalge Nunc
International, USA), and incubated at room temperature for 1 h
or overnight at 4uC. The plate was washed three times with PBST
and blocked with 1% BSA/PBS for 1 h. After removal of the
blocking solution, 100 ml of 5 mg ml21 DIG-labeled protein or
DIG-labeled bacteria (OD600 at 0.04) was added and incubated at
room temperature for 90 min or at 4uC overnight. Following
vigorous washing in PBST (5 washes with 5 min soaking times),
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100 ml of anti-DIG HRP conjugate (Roche), diluted 1:5000 in 1%
BSA/PBS, was added to wells and incubated for 1 h. Plates were
again vigorously washed and color developed by adding 100 ml
ABTS substrate (Roche). Plates were read with an ELISA reader
(Biotek EL800) at an absorbance of 405 nm. Alternatively, for
unlabelled LamR, 100 ml of protein (5 mg ml21) was added to
coated wells. After washing, bound LamR was detected using
rabbit polyclonal anti-LamR (diluted 1:1000) in 1% BSA/PBS
followed by goat anti-rabbit IgG-HRP conjugate (Sigma; diluted
1:10,000). Inhibition assays were performed as described above,
except that 0.5 mg aliquots of DIG-labeled LamR were pre-
incubated with 0.5–100 mg of peptide for 4 h at room temperature
prior to being added to coated wells. OD values shown are minus
OD values obtained from control wells coated with 100 ml aliquots
of 1% BSA. Statistical significance was determined using two-
tailed Student’s t test.
Synthetic peptides
The synthetic PorA and OmpP2 peptides utilized in this study
are detailed in Table 1. All were synthesized (high purity grade;
peptide purity .95%) by GenScript, USA.
PorA loop 4 truncation in N. meningitidis
A 42-bp deletion in the coding sequence of MC58 porA was
introduced into a previously constructed plasmid, pPorA-4d
(Table S1), by inverse PCR using primers L4-F1 and L4-R1
(Table S2). Amplification resulted in a product containing the
desired deletion and incorporating unique BglII and BamHI sites,
thus allowing re-ligation of the fragment to form pPorADL4 (Table
S1). Inverse PCR using primers L4-F2 and L4-R2 was then used
to introduce a BglII site downstream of porA, into which a BglII-
digested V cassette (encoding resistance to spectinomycin and
streptomycin) [45] was inserted to form pPorADL4V (Table S1).
This plasmid was subsequently used to mutate N. meningitidis
MC58 by natural transformation and allelic exchange as
previously described [46]. The porA loop 4 deletion in the resulting
mutant (MC58PorAD197–210) was confirmed by PCR analysis and
DNA sequencing. Growth curve assays carried out using liquid
cultures showed no significant differences between
MC58PorAD197–210 and the wild-type strain (data not shown).
The pilQ knockout mutation was subsequently introduced into this
strain to generate MC58PorAD197–210DpilQ using previously
described methods [22].
OmpP2 loop 2 truncation in H. influenzae
A 2.7-kb region containing the ompP2 gene and flanking DNA
was amplified from H. influenzae Rd KW20 using primers F1 and
mP2_R (Table S2) and TA-cloned into pGEM-T Easy to yield
pMSA8 (Table S1). This template was subject to inverse PCR
using OmgF and OmgR primers, thus incorporating BamHI
restriction sites into the amplicon and a copy of a DNA uptake
sequence (59-AAGTGCGGTCA-39) which is required for efficient
DNA uptake by H. influenzae [47]. The BamHI site was used to
introduce a BamHI-digested kanamycin resistance cassette down-
stream of, and in the same orientation as ompP2, to generate
pMSA15. Inverse PCR utilizing primers P2DL2I_F and
P2DL2I_R was subsequently used to remove the nucleotides
encoding OmpP2 amino acids 91–99. Use of P2DL2I_F and
P2DL2I_R incorporated BglII-sites into the amplicon, thus
allowing re-ligation to form pMSA16. Nucleotide sequencing
revealed a single base pair deletion present in the 59 end of the
ompP2 coding sequence in pMSA8 and in subsequent constructs
which would lead to premature translation of ompP2 in H.
influenzae. To repair this, a 539-bp mega primer spanning the
mutated region was amplified from Rd KW20 chromosomal DNA
using primers F1 and MegaR (Table S2). The mega primer was
then used in conjunction with primer mP2_R using pMSA16 as
template to generate a linear repaired mutagenic product
comprising of upstream flanking sequence, ompP2 lacking nucle-
otides encoding loop 2, kanamycin resistance cassette and
downstream flanking sequence. This product was used to naturally
transform H. influenzae Rd KW20 using a previously described
method for the natural transformation of N. meningitidis [46]. The
ompP2 loop 2 deletion in the resulting mutant (RdOmpP2D91–99)
was confirmed by PCR analysis and DNA sequencing. Growth
curve assays carried out using liquid cultures showed no significant
differences between RdOmpP2D91–99 and the wild-type strain
(data not shown).
Mutation of OmpP2 in H. influenzae
796-bp of ompP2 was removed from pMSA15 by inverse PCR
using primers DP2F and P2DL2I_R. These primers incorporated
BglII-sites allowing re-ligation of the amplicon to form pMSA17
(Table S1). This PCR template was then used in conjunction with
primers F1 and P2FR to yield a linear mutagenic PCR product
that was used to naturally transform H. influenzae Rd KW20 using
a previously described method [46]. The ompP2 deletion in the
resulting mutant (RdDompP2) was confirmed by PCR analysis and
DNA sequencing. Growth curve assays carried out using liquid
cultures showed no significant differences between RdDompP2 and
the parental strain (data not shown).
Cell fractionation and confocal microscopy
Cell fractionation was undertaken as described previously [48].
For confocal microscopy, growth from overnight cultures was
harvested by centrifugation (40006 g for 10 min), resuspended in
16PBS, and the OD600 adjusted to 1.0. 50 ml aliquots were then
added to Knittel adhesive glass slides (SLS) and left at room
temperature for 1 h. Bacteria were fixed using 4% paraformalde-
hyde for 10 min. Slides were washed four times in 16 PBS and
then blocked with 1% BSA/PBS for 1 h. Surface-accessible PorA
was labeled with mouse anti-meningococcal serosubtype P1.7
monoclonal primary antibody (1:25 diluted; NIBSC code: 01/514)
for 1 h. Following washing in 16 PBS, goat anti-mouse IgG-
cascade blue conjugate (1:800 diluted; Invitrogen) was added for
1 h. Following further washes in 16 PBS, membranes were
stained with FM1-43 (10 mM; Invitrogen) in Hank’s Balanced Salt
Solution (Invitrogen) for 30 min in the dark. Following a final 16
PBS wash, coverslips were mounted with Prolong Gold anti-fade
(Invitrogen) and images acquired on a Zeiss LSM700 confocal
microscope using a 636 objective. Images are single sections
(300 nm) and data was collected from different fluorophores in
separate channels. Images were processed using Image J and
Adobe Photoshop.
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